Breast cancer subtyping from plasma proteins

BMC Medical Genomics

Volumn 6, Issue SUPPL.1, 2013, Pages

  Zhang, Fan ^a   Chen, Jake Y ^b,c  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA PROTEIN;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CONTROLLED STUDY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN ANALYSIS; PROTEOMICS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

ADULT; ALGORITHMS; BIOLOGICAL MARKERS; BLOOD PROTEINS; BREAST NEOPLASMS; CLUSTER ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOME; PROTEOMICS;

EID: 84872965978     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-6-S1-S6     Document Type: Article

References (41)

1. Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology. Hu X, Zhang Y, Zhang A, Li Y, Zhu Z, Shao Z, Zeng R, Xu LX, OMICS 2009 13 4 291 300 10.1089/omi.2009.0016 19624269
2. Proteomic analysis of archival breast cancer serum. Zeidan BA, Cutress RI, Murray N, Coulton GR, Hastie C, Packham G, Townsend PA, Cancer Genomics Proteomics 2009 6 3 141 147 19487543
3. Diagnosis of breast cancer by tear proteomic pattern. Lebrecht A, Boehm D, Schmidt M, Koelbl H, Schwirz RL, Grus FH, Cancer Genomics Proteomics 2009 6 3 177 182 19487546
4. Breast cancer: origins and evolution. Polyak K, J Clin Invest 2007 117 11 3155 3163 10.1172/JCI33295 17975657 (Pubitemid 350096968)
5. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Proc Natl Acad Sci USA 2001 98 19 10869 10874 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
6. Molecular portraits of human breast tumours. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Nature 2000 406 6797 747 752 10.1038/35021093 10963602
7. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. JAMA 2006 295 21 2492 2502 10.1001/jama.295.21.2492 16757721 (Pubitemid 43854964)
8. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN, Clin Med Res 2009
9. Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: clinical implications. Suzuki M, Tarin D, Mol Oncol 2007 1 2 172 180 10.1016/j.molonc.2007.03.005 19383293 (Pubitemid 47199131)
10. Gene expression profiling predicts clinical outcome of breast cancer. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Nature 2002 415 6871 530 536 10.1038/415530a 11823860 (Pubitemid 34130608)
11. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al. Lancet 2005 365 9460 671 679 15721472 (Pubitemid 40260888)
12. A gene expression signature that defines breast cancer metastases. Ellsworth RE, Seebach J, Field LA, Heckman C, Kane J, Hooke JA, Love B, Shriver CD, Clin Exp Metastasis 2009 26 3 205 213 10.1007/s10585-008-9232-9 19112599
13. Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Hynes RO, Cell 2003 113 7 821 823 10.1016/S0092-8674(03)00468-9 12837240 (Pubitemid 36792026)
14. Comprehensive label-free method for the relative quantification of proteins from biological samples. Higgs RE, Knierman MD, Gelfanova V, Butler JP, Hale JE, J Proteome Res 2005 4 4 1442 1450 10.1021/pr050109b 16083298 (Pubitemid 41208703)
15. Protein interactions and disease: computational approaches to uncover the etiology of diseases. Kann MG, Brief Bioinform 2007 8 5 333 346 10.1093/bib/bbm031 17638813 (Pubitemid 350142622)
16. Discovery of pathway biomarkers from coupled proteomics and systems biology methods. Zhang F, Chen JY, BMC genomics 2010 11 Suppl 2 12 10.1186/1471-2164-11-S2-S12 21143795
17. Breast cancer plasma protein biomarker discovery by coupling LC-MS/MS proteomics and systems biology. Zhang F, Wang M, Chen JY, Proceedings of the First ACM International Conference on Bioinformatics and Computational Biology; Niagara Falls, New York 1854858 463 465 ACM 2010
18. From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Laganiere J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V, Proc Natl Acad Sci USA 2005 102 33 11651 11656 10.1073/pnas.0505575102 16087863 (Pubitemid 41170781)
19. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, et al. PLoS Genet 2008 4 4 1000054 10.1371/journal.pgen. 1000054 18437204 (Pubitemid 351656691)
20. HPD: an online integrated human pathway database enabling systems biology studies. Chowbina SR, Wu X, Zhang F, Li PM, Pandey R, Kasamsetty HN, Chen JY, BMC Bioinformatics 2009 10 Suppl 11 5 10.1186/1471-2105-10-S11-S5 19958515
21. IPAD: the Integrated Pathway Analysis Database for Systematic Enrichment Analysis. Zhang F, Drabier R, BMC Bioinformatics 2012 13 Suppl 15 7 10.1186/1471-2105-13-S15-S7 23176383
22. Label-free mass spectrometry-based protein quantification technologies in proteomic analysis. Wang M, You J, Bemis KG, Tegeler TJ, Brown DP, Brief Funct Genomic Proteomic 2008 7 5 329 339 10.1093/bfgp/eln031 18579615
23. Statistical significance for genomewide studies. Storey JD, Tibshirani R, Proc Natl Acad Sci USA 2003 100 16 9440 9445 10.1073/pnas.1530509100 12883005 (Pubitemid 37033947)
24. HPD: An Online Integrated Human Pathway Database Enabling Systems Biology Studies. Chowbina SR, Wu X, Zhang F, Li PM, Pandey R, Kasamsetty HN, Chen JY, BMC Bioinformatics 2009
25. Characterizing Mergeability of Human Molecular Pathways, submitted. Wu X, Chowbina SR, Li PM, Pandey R, Kasamsetty HN, Chen JY
26. Comprehensive molecular portraits of human breast tumours. Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton LL, Dooling DJ, Ding L, Mardis ER, et al. Nature 2012
27. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Proc Natl Acad Sci USA 2001 98 19 10869 10874 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
28. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, Nguyen C, Xerri L, Houlgatte R, Jacquemier J, et al. Cancer Res 2005 65 6 2170 2178 10.1158/0008-5472.CAN-04-4115 15781628 (Pubitemid 40490124)
29. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM, Breast Cancer Res 2010 12 5 68 10.1186/bcr2635 20813035
30. Repeated observation of breast tumor subtypes in independent gene expression data sets. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Proc Natl Acad Sci USA 2003 100 14 8418 8423 10.1073/pnas.0932692100 12829800 (Pubitemid 36842560)
31. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Marcotte R, Brown KR, Suarez F, Sayad A, Karamboulas K, Krzyzanowski PM, Sircoulomb F, Medrano M, Fedyshyn Y, Koh JL, et al. Cancer discovery 2012 2 2 172 189 10.1158/2159-8290.CD-11-0224 22585861
32. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET, Proc Natl Acad Sci USA 2003 100 18 10393 10398 10.1073/pnas.1732912100 12917485 (Pubitemid 37071889)
33. The human disease network. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL, Proc Natl Acad Sci USA 2007 104 21 8685 8690 10.1073/pnas. 0701361104 17502601 (Pubitemid 47175372)
34. Persistent complement activation on tumor cells in breast cancer. Niculescu F, Rus HG, Retegan M, Vlaicu R, Am J Pathol 1992 140 5 1039 1043 1374587
35. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis. Woodhouse CS, Morgan AC Jr, Cancer Res 1989 49 10 2766 2772 2713860 (Pubitemid 19143413)
36. Role of ErbB4 in breast cancer. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi OP, Elenius K, J Mammary Gland Biol Neoplasia 2008 13 2 259 268 10.1007/s10911-008-9079-3 18454307
37. Transforming growth factor alpha and mouse models of human breast cancer. Humphreys RC, Hennighausen L, Oncogene 2000 19 8 1085 1091 10.1038/sj.onc. 1203278 10713694 (Pubitemid 30153794)
38. RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors. Patel AS, Murphy KM, Hawkins AL, Cohen JS, Long PP, Perlman EJ, Griffin CA, Cancer Genet Cytogenet 2007 176 2 107 114 10.1016/j.cancergencyto.2007.04.004 17656252 (Pubitemid 47081195)
39. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Andre F, Mazouni C, Liedtke C, Kau SW, Frye D, Green M, Gonzalez-Angulo AM, Symmans WF, Hortobagyi GN, Pusztai L, Breast Cancer Res Treat 2008 108 2 183 190 10.1007/s10549-007-9594-8 17468948 (Pubitemid 351311360)
40. Proteomics and Bioinformatics Approaches for Identification of Serum Biomarkers to Detect Breast Cancer. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW, Clinical Chemistry 2002 48 8 1296 1304 12142387 (Pubitemid 34809839)
41. Conditions for the effectiveness of a preliminary test of variance. Markowski CA, Markowski EP, American Statistician 1990 44 322 326